Drug Price Law to Demand Close FDA Coordination With Medicare

The FDA aims to work with Medicare officials to ensure a landmark drug pricing law won’t hinder development of alternatives to costly brand-name medicines, the head of the FDA’s drug center said Monday.

Close collaboration with the Centers for Medicare & Medicaid Services “will be central” as the Medicare agency implements provisions of the Inflation Reduction Act, Patrizia Cavazzoni, director of the Food and Drug Administration’s Center for Drug Evaluation and Research, said in remarks at the Association for Accessible Medicine’s Generics and Biosimilars Conference.

“There are certain areas that will require us to communicate to a greater extent” with ...